Extranodal Non-Hodgkin Lymphoma — Trials

Extranodal Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

261 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 18
Ph III recruiting: 1
Growth YoY: —
Industry share: 13%
Top sponsor: Ruijin Hospital
Termination share: 32.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04414163	A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type	active not recruiting	Phase 2	23	ImmuneOncia Therapeutics Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT06647732	Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)	active not recruiting	Phase 2	42	Sun Yat-sen UniversityOTHER	1	Sep 15, 2026	clinicaltrials